Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

3 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for Relapsed or Refractory Multiple Myeloma, a type of blood cancer that has returned or is not responding to previous treatments. The study will explore different combinations of medications to find the most effective treatment. The medications being tested include Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Bortezomib, and Dexamethasone. Some of these medications are given as tablets or capsules, while others are administered through injections.

The purpose of the study is to compare the effectiveness of these medication combinations. Participants will be randomly assigned to receive one of the following treatments: Talquetamab with Pomalidomide, Talquetamab with Teclistamab, or a combination chosen by the investigator, which could be Elotuzumab, Pomalidomide, and Dexamethasone, or Pomalidomide, Bortezomib, and Dexamethasone. Some participants may receive a placebo. The study will last for a period of up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of the disease.

Throughout the study, the main focus will be on measuring how long participants live without the disease getting worse, known as progression-free survival. This will help researchers understand which treatment combination works best for patients with relapsed or refractory multiple myeloma. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

1 joining the study

Upon joining the study, the patient will be randomly assigned to one of the treatment groups. The study involves comparing different combinations of medications for treating relapsed or refractory myeloma.

2 treatment group assignment

The patient may be assigned to one of the following treatment groups: Talquetamab with Pomalidomide (Tal-P), Talquetamab with Teclistamab (Tal-Tec), or the investigator’s choice of either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd).

3 medication administration

The medications will be administered in various forms: oral tablets or capsules, subcutaneous injections, or intravenous infusions. The specific medications and their administration routes are as follows:

Dexamethasone: Oral tablets.

Pomalidomide: Oral capsules.

Talquetamab: Subcutaneous injection.

Teclistamab: Subcutaneous injection.

Bortezomib: Subcutaneous injection.

Elotuzumab: Intravenous infusion.

4 treatment duration

The treatment will continue as per the study protocol, with regular monitoring and assessments to evaluate the patient’s response to the treatment. The study aims to compare the effectiveness of the different treatment combinations.

5 monitoring and assessments

Throughout the study, the patient’s health and response to the treatment will be closely monitored. This includes regular check-ups, laboratory tests, and assessments to track the progression of the disease and any side effects of the medications.

6 study completion

The study is expected to conclude by June 2027. Upon completion, the results will be analyzed to determine the most effective treatment combination for relapsed or refractory myeloma.

Who Can Join the Study?

  • Be at least 18 years old or the legal age of consent in the area where the study is happening.
  • Have a confirmed diagnosis of multiple myeloma, which is a type of blood cancer, as defined by specific medical criteria.
  • Have a measurable disease at the time of screening, which means the disease can be detected and measured by tests. This can be shown by certain levels of proteins in the blood or urine.
  • Have a relapsed or refractory disease. Relapsed means the disease returned after responding to treatment. Refractory means the disease did not respond well to treatment.
  • Show evidence of the disease getting worse or not responding to the last treatment, as determined by the study doctor.
  • Have an ECOG performance status score of 0, 1, or 2. This score is used to assess how well a person can perform daily activities. A score of 0 means fully active, 1 means some symptoms but nearly fully active, and 2 means unable to work but able to do most self-care activities.

Who Cannot Join the Study?

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Other Sites

Site Name City Country Status
Azienda Sanitaria Locale Di Taranto Taranto Italy
Ospedale San Raffaele S.r.l. Milan Italy
Fakultni Nemocnice Hradec Kralove Novy Hradec Kralove Czechia
Semmelweis University Budapest Hungary
Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet Budapest Hungary
Centre Hospitalier Universitaire De Nantes Nantes France
Hopital Beaujon Clichy France
Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej Biala Podlaska Poland
St. Antonius Ziekenhuis Nieuwegein The Netherlands
University Hospital Olomouc Olomouc Czechia
Hbyy Hiegdvck Hague The Netherlands
Usfspwnfpd Oy Doprmqsl Debrecen Hungary
Iapwkdrr Pwovvbqrolfwuwp Clqlds Cyivbj Marseille France
Hmegqrcp Vpjm dhknpjaz Barcelona Spain
Ovxhvo Uzpcvhprph Hnuckmza Odense Denmark
Ufilkilkbmymnxeicsltj Ttnotswyo Awo Tuebingen Germany
Fiyagsjgrw Iqdat Cs Gqwdwa Oerjnkup Mulsubku Phpbupwybec Milan Italy
Fejycnupzy Iouqu Ptaccjglzsl Srq Mzdfdw Pavia Italy
Rzjokf Sarkx Scicsf Ufcyaglnspvcsjugbah Lund Sweden
Uatvvizuyugnyqaca Dqork Slvsh Dd Vmydsc Verona Italy
Awetrugqm Hntxjduy Athens Greece
Uaoesnx Uxzkutqeim Hiwtfpxy Uppsala Sweden
Fexrotmj Nbaqttsrb Btce Brno Czechia
Cuvdeq Hpzfozeyfee Rgvuuxqw Uvfjgfqiickte Df Txsza Tours France
Ipqza Ocopnxox Pnainslabpr Saj Mqbyczk Genoa Italy
Ucsfltokrwsl De Syfiuhis Dv Cizvhzmwbe Santiago De Compostela Spain
Awqbwht Ogolkktxfld Ullqqychzfsic Cwmwvmkadwpu Dqjei Swgyvr E Dkjrn Slgnzbj Du Ttysvh Turin Italy
Unmedsigotrgelyyelope Hmsvqjrkxm Ast Heidelberg Germany
Uzdaufjbyg Ot Szdati Szeged Hungary
Adooldb Uucaw Syknorgka Lkwdic Dt Bfdyoor Bologna Italy
Upyywypftqbh Zsgzudbpjr Griw Gent Belgium
Ckjzvz Hcdvpumjoqj Lobw Smr Pierre Benite France
Htdhbiui Ufnozchtscinj Mvyoidr Dn Vyxrxxfikd Santander Spain
Swgpyu Da Sbpqz Dd Lib Ipplk Bfsgfoa Palma Spain
Fznyekzkj Powz Lk Igfngysunhvtt Bdrbpnitn Dzp Hbwllgmp Udcojgrshotcf Ll Pzs Madrid Spain
Cakeauu Osbjhlhrs Zunvp Lmitkbqofo Ixu Sfx Jznw Z Dbzia Lublin Poland
Vsfvh Sint-Niklaas Belgium
Symwa Wiuj Wbtgdi Ghvqrprbennsioomwe Vienna Austria
Hivpjnxn Uxkmcwzhzeima Vlsfdj Df Los Nqnoel Granada Spain
Tysoryegaz Crpaxs Hryhdcjt Thessaloniki Greece
Fbslkgoq Nizlzuelf Onvjgkj Ostrava Czechia
Cumoaiapp Zxadffmckn Suhhdjphc Eindhoven The Netherlands
Abflgb Ujsemfcljd Hgfvqtlj Aarhus Denmark
Sgozcvfmveeesyufmqvoqs Vxlqkxtxa Ocscgmyebpha Nyiregyhaza Hungary
Hljktwvx Ujniiyahuuyha Dzgeabqp Donostia / San Sebastian Spain
Hdhlwaom Unmhdppuuttda Liyra Ariauyz Lugo Spain
Acibusp Oefpxrkojkh Nlbtdulgb Su Anuoocr E Bmyrwj E C Axlobr Amrtqpdwjqa Alexandria Italy
Sunhgrlhyjexuc Czxagmd Otvagomhj Smbfttynosn Psecxwhtm Zplmma Ommcsn Zzepjatyju W Kggrayjs Kielce Poland
2aq Avm Fbpcv Gjovssi Hiqgiaef Athens Greece
Zhgskctrwq Ofua Luvaedm Genk Belgium
Uvxnibwsyc Os Pcfi Pecs Hungary
Arksvdx Uiezi Sasbzlpqb Lpnhsj Dvthg Roayunt Faenza Italy
Redegk Vpsoyapvlxxyp Umea Sweden
Igdly Kiurjpjgw Smvjfthir Zwolle The Netherlands
Mvkblhbefduffwvscynzopbnnr Hzvtljivabbidwkw Halle (Saale) Germany
Uuwetpggrnhqlnluyoiyb Acjffiwe Augsburg Germany
Asnxj Gkbzaqptc Do Ccbqqga Catania Italy
Hjrqxbii Syh Pqwxd Dq Alrepfwof Caceres Spain
Awvr Dw Sravx Dc Bgqrce Y Sfwop Burgos Spain
Gultq Hitszbv Di Chxyiishw Charleroi Belgium
Sqfi Cszhh Gsmcpoxmwx Salzburg Austria
Ssoezfy Sxykryiovygwezv W Betgmwrvg Poqbqvmjuwm Ojfehvi Oxhvufthcpnq Izcspazkmomxijmbiqk Brzozow Poland
Fgogjradsnfryfg Smegoznjp Almere The Netherlands
Avxqjzn Syicb Ssrbdnrbq Tsbfoqwzngkt Oswal Mbzeravs Legnano Italy
Azypjoj Spsufagmw Lmyfbt Dc Povxklm Pescara Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
22.02.2024
Belgium Belgium
Not recruiting
22.02.2024
Czechia Czechia
Not recruiting
22.02.2024
Denmark Denmark
Not recruiting
22.02.2024
France France
Not recruiting
22.02.2024
Germany Germany
Not recruiting
22.02.2024
Greece Greece
Not recruiting
22.02.2024
Hungary Hungary
Not recruiting
22.02.2024
Italy Italy
Not recruiting
22.02.2024
Poland Poland
Not recruiting
22.02.2024
Spain Spain
Not recruiting
22.02.2024
Sweden Sweden
Not recruiting
22.02.2024
The Netherlands The Netherlands
Not recruiting
22.02.2024

Trial locations

Talquetamab: This medication is being tested in combination with other treatments to see how well it works for patients with relapsed or refractory myeloma. It is a new type of therapy that targets specific proteins on cancer cells to help the immune system attack them.

Pomalidomide: This is a medication used to treat multiple myeloma. It works by helping the immune system fight cancer and by stopping the growth of cancer cells.

Teclistamab: This is an investigational drug being studied for its potential to treat multiple myeloma. It is designed to help the immune system recognize and destroy cancer cells.

Elotuzumab: This medication is used in combination with other drugs to treat multiple myeloma. It works by targeting a specific protein on the surface of cancer cells, helping the immune system to attack them.

Bortezomib: This is a medication used to treat multiple myeloma. It works by interfering with the growth of cancer cells, eventually leading to their death.

Dexamethasone: This is a steroid medication used to reduce inflammation and suppress the immune system. In cancer treatment, it is often used to help reduce side effects and improve the effectiveness of other cancer therapies.

Investigated Diseases:

Relapsed or Refractory Myeloma – This is a type of cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this condition, the myeloma has either returned after treatment (relapsed) or has not responded to treatment (refractory). The disease progresses as abnormal plasma cells multiply, leading to bone damage, kidney problems, and a weakened immune system. Patients may experience symptoms such as bone pain, fatigue, and frequent infections. Over time, the disease can cause significant damage to bones and other organs. The progression of the disease varies, and it can become more challenging to manage as it advances.

Trial ID:
2022-502446-27-00
Protocol code:
64407564MMY3009
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Germany
  • A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1
    Belgium Czechia France Germany Greece Italy +3